SLC5A2 and metabolic syndrome: Since SGLT2 inhibitors were used in clinic as hypoglycemic agents, considerable results have been achieved, such as lowering blood glucose, improving glycosylated hemoglobin, and reducing cardiovascular risk.[22–25] Nevertheless, there is no doubt that SGLT2 inhibitors cause dyslipidemia as well as therapeutic effects.